Pharmaceuticals

According to a research report this morning, J.P. Morgan decreases its PT on MAP Pharmaceuticals (NASDAQ: MAPP) from $23 to $22 awaiting FDA feedback on Levadex CRL. J.P. Morgan stated, “While clearly not the best-case outcome, we are encouraged that the FDA did not find any issues relating to the...

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today provided an update on LEVADEX®, the Company's investigational orally inhaled drug for the potential acute treatment of migraine in adults. The Company submitted a request to the U.S. Food and Drug Administration for a meeting to discuss the Complete...

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2011. The net loss for the fourth quarter ended December 31, 2011 was $13.8 million, compared to a net loss of $13.9 million during the same period in 2010. The net loss...

In recent years, traders and investors have increasingly turned to social media to discuss their investments. Now, interested parties can get a scientific look at what is being discussed on a weekly, monthly, and even hourly basis. Provided by Social Market Analytics, here is the morning social...

In recent years, traders and investors have increasingly turned to social media to discuss their investments. Now, interested parties can get a scientific look at what is being discussed on a weekly, monthly, and even hourly basis. Provided by Social Market Analytics, here is the morning social...

Shares of MAP Pharmaceuticals (NASDAQ: MAPP) are seeing much weakness during Tuesday's pre-market trading session after the company received a complete response letter from the FDA yesterday after the close on its LEVADEX drug. In the Complete Response letter, the FDA requested that MAP Pharma...

MAP Pharmaceuticals Inc (NASDAQ: MAPP) dipped 23.28% to $13.15 in the pre-market session. The US Food and Drug Administration rejected MAP Pharmaceuticals' orally inhaled treatment for migraine. Apollo Group Inc (NASDAQ: APOL) moved down 6.83% to $40.2501 in the pre-market session. Apollo Group...

JP Morgan has published a research report on MAP Pharmaceuticals (NASDAQ: MAPP) after the company's FDA approval delay due to yesterday's complete response letter. In the report, JP Morgan writes, "[Yesterday] after the close, MAP announced that the FDA has issued a complete response letter (CRL)...

Canaccord Genuity has published a research report on MAP Pharmaceuticals (NASDAQ: MAPP) commenting on the copmany's current cash balance. In the report, Canaccord writes, "The issues relating to CMC will likely be the primary focus, with the complete review of the inhaler usability information...

Tuesday, March 27, 2012 This is your Benzinga news summary and trader's outlook covering headlines from overnight and today's pre-market session. Benzinga's Top News McCormick (NYSE: MKC) Reports Q1 EPS $0.55 vs $0.53 Est; Revenues $906.7M vs $869.81M Est MAP Pharmaceuticals (NASDAQ: MAPP)...

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Patent and Trademark Office (USPTO) issued to the Company U.S. Patent No. 8,119,639, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile." The...

Canaccord Genuity has initiated coverage on the following companies: Hi-Tech Pharmacal (NASDAQ: HITK) Buy, $45 PT MAP Pharmaceuticals (NASDAQ: MAPP) Buy, $24 PT Pernix Therapeutics (NYSE: PTX) Buy, $15 PT

Shares of MAP Pharmaceuticals (NASDAQ: MAPP) are higher on the session by 3.79%, currently trading at $13.97. The stock has been moving largely higher over the past three weeks and is currently testing the 50-day moving average. Options traders are focusing on puts today. The strike seeing the...

JP Morgan has initiated coverage on Map Pharmaceuticals (NASDAQ: MAPP) with an Overweight rating and $23 price target.

Piper Jaffray released a research report on Jazz Pharmaceuticals (NASDAQ: JAZZ) announcing they are not expecting payer pushback in the wake of most recent Xyrem price hike. In its report, Jazz Pharmaceuticals writes that, “Beginning today, Jazz is implementing a near 20% price increase for...